News reports across the country trumpet major mergers and consolidation involving health insurers, physician practices, pharmacy benefit managers, hospitals and health systems, and other providers, including many that integrate different services under a single umbrella. The wave of consolidation and integration has federal and state policy makers examining how it affects competition, prices, and overall costs.

Three experts joined moderator Larry Levitt for a discussion about health care consolidation and integration. The panelists discussed the motivations behind horizontal and vertical consolidation in health care, its potential to lower or raise costs, the implications for patients and payers, and how policy makers could respond.

Hosted on Acast. See acast.com/privacy for more information.

Amid perennial public concern about the cost of prescription drugs, the Trump administration has undertaken a raft of efforts to push or persuade drug manufacturers to lower drug prices. These include “Most Favored Nation” proposals that would tie U.S. drug prices to the lowest cost in other countries and encouraging manufacturers to make more drugs available for sale directly to consumers at discounted prices. To date, the administration has inked two voluntary deals with pharmaceutical companies to sell drugs to the Medicaid program at most-favored nation pricing and launch new drugs in the U.S. at the same price as in other countries in exchange for a three-year reprieve from new tariffs on their products. The administration also set up a website, Trumprx.gov, scheduled to launch in 2026, through which it plans to connect consumers to manufacturers and other vendors enabling direct-purchase of prescription drugs.

On November 20 , three experts joined Larry Levitt, executive vice president for health policy at KFF, for a 4“Health Wonk Shop” discussion about the latest developments in prescription drug pricing and what they mean for drug manufacturers, patients and public and private health insurance programs. Among the questions to be discussed include:

• How did the administration’s efforts to lower drug prices square with drug price negotiation in Medicare, and a provision in the One Big Beautiful Bill Act that allows drug companies to exempt more products from those negotiations?
• Are the Trump administration’s moves translating into lower drug prices for consumers? Which consumers might benefit most from these efforts? Are those prices at least as low as those paid for the same drugs in comparable countries?
• How will the availability of drugs be affected, if at all?
• What might the effects be on drug prices in other countries?
• How effective will voluntary agreements with drug companies be over time?

Hosted on Acast. See acast.com/privacy for more information.

President Trump signed into law in July a budget reconciliation package that mandates all adults who are eligible for Medicaid through the ACA expansion meet federal work and reporting requirements. At a minimum, the 41 states (including D.C.) that have expanded Medicaid under the ACA will be required to verify that individuals are working or meet certain exemptions when they apply for or renew their Medicaid coverage.

Four experts, including two state Medicaid directors, joined Health Wonk Shop series moderator Larry Levitt for an hour-long discussion of how states will go about implementing the new Medicaid work requirements.

Hosted on Acast. See acast.com/privacy for more information.